{"id":390423,"date":"2019-05-15T00:00:00","date_gmt":"2019-05-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0028-2018-biopharma-major-depressive-disorder-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-25T11:36:33","modified_gmt":"2026-04-25T11:36:33","slug":"algocg0028-2018-biopharma-major-depressive-disorder-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0028-2018-biopharma-major-depressive-disorder-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Major Depressive Disorder | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>Major depressive disorder (<abbr title=\"major depressive disorder\">MDD<\/abbr>) is a highly drug-treated condition that uses an array of drug classes including, but not limited to, serotonin reuptake inhibitors (<abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s), selective serotonin\/norepinephrine reuptake inhibitors (<abbr title=\"serotonin\/norepinephrine reuptake inhibitor\">SNRI<\/abbr>s), and\u2014as adjunctive therapies\u2014atypical antipsychotics. Even though the <abbr title=\"major depressive disorder\">MDD<\/abbr> drug market is entrenched with generic therapies, <abbr title=\"major depressive disorder\">MDD<\/abbr> patients\u2019 heterogeneous response to antidepressants and\/or atypical antipsychotics afford branded drugs (e.g., Trintellix [Lundbeck\/Takeda], Rexulti [Otsuka Pharmaceuticals\/Lundbeck]) the opportunity to be introduced into the treatment paradigm, often as later-line therapies. Given <abbr title=\"major depressive disorder\">MDD<\/abbr>\u2019s crowded and competitive landscape, it is valuable for drug marketers and developers to understand how <abbr title=\"major depressive disorder\">MDD<\/abbr> patients are being treated using real-world data.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"major depressive disorder\">MDD<\/abbr> patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed <abbr title=\"major depressive disorder\">MDD<\/abbr> patients?<\/li>\n<li>How have antidepressants and atypical antipsychotics been integrated into the treatment algorithm?<\/li>\n<li>What proportion of <abbr title=\"major depressive disorder\">MDD<\/abbr> patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"major depressive disorder\">MDD<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"major depressive disorder\">MDD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis <\/em>provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess theirsource of business and quantify areas of opportunity for increasing their brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390423","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390423\/revisions"}],"predecessor-version":[{"id":393548,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390423\/revisions\/393548"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}